MCI-9042, the new selective antagonist of serotonergic (5-HT(2A)) receptors

Cardiovascular Drug Reviews

Volumn 15, Issue 2, 1997, Pages 101-121

  Takada, Yumiko ^a   Takada, Akikazu ^a   Urano, Tetsumei ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 HT receptor; 5 HT(2A); Antithrombotic drugs; MCI 9042; Serotonin; Thrombosis

Indexed keywords

CALCIUM ION; PHOSPHATIDYLINOSITOL; SARPOGRELATE; SEROTONIN 2A RECEPTOR;

BUERGER DISEASE; CALCIUM CELL LEVEL; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ERYTHROCYTE SHAPE; HEART RATE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MUSCLE TONE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOSIS; UREMIA; VASCULAR SMOOTH MUSCLE;

EID: 0030815167     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.1997.tb00326.x     Document Type: Review

References (41)

1. Betteridge DJ, Zahavi J, Jones NA, Shine B, Kakkar VV, Galton DJ. Platelet function in diabetes mellitus in relationship to complications, glycosylated haemoglobin and serum lipoproteins. Eur J Clin Invest 1981;11:273-277.
2. Brogden RN, Sorkin EM. Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease. Drugs 1990;40:903-949.
3. Cohen RA, Vanhoutte PM. Platelets, serotonin, and endothelial cells. In: Vanhoutte PM, ed. Serotonin and cardiovascular disease. New York: Raven Press, 1985.
4. Colwell JA, Winocour PD, Lopes VM, Halushka PV. New concepts about the pathogenesis of atherosclerosis in diabetes mellitus. Am J Med 1983;75:67-80.
5. Dallinger KJ, Jennings PE, Toop MJ, Gyde OH, Barnett AH. Platelet aggregation and coagulation factors in insulin dependent diabetics with and without microangiopathy. Diab Med 1987;4:44-48.
6. De Clerck F, de Chaffoy de Courcelles D. Amplification mechanisms in platelet activation. In: Meyer P, Marche P, eds. Blood Ceils and Arteries in Hypertension and Atherosclerosis. New York: Raven Press, 1989.
7. De Clerck F, van Nueten JM. Platelet-mediated vascular contractions; inhibition of the serotonergic components by ketanserin. Thromb Res 1982;27:713-727.
8. Eknoyan G, Brown C 3d. Biochemical abnormalities of platelets in renal failure. Evidence for decreased platelet serotonin, adenosine diphosphate and Mg-dependent adenosine triphosphatase. Am J Nephrol 1981; 1:17-23.
9. Erickson RV, Williman M, Pendras JP. A true hypercoagulability state in patients on chronic hemodialysis. Trans Am Soc Art Int Organs 1966;12:205-206.
10. Furukawa K, Tanabe T, Mishima Y, et al. Clinical effect on chronic arterial occlusive diseases of sarpogrelate hydrochloride (MCI-9042)-A multicenter dose finding study-. J Clin Thrap Med 1991;7:1193-1204.
11. Gordge MP, Faint RW, Rylance PB, Neild GH. Platelet function and the bleeding time in progressive renal failure. Thromb Haemost 1988;60:83-87.
12. Hara H, Kitajima A, Shimada H, Tamao Y. Antithrombotic effect of MCI-9042, a new antiplatelet agent on experimental thrombosis models. Thromb Haemost 1991;66:484-488.
13. Hara H, Kitajima A, Tamao Y. Improvement of red blood cell deformability by a new anti-platelet agent, MCI-9042. Clin Hemorheol 1992;12:267-277.
14. 2-serotonergic receptor antagonist. Thromb Haemost 1991;65:415-420.
15. Hara H, Osakabe M, Yamada K, Nakao K, Tamao Y. Effect of sarpogrelate hydrochloride on contraction of blood vessel. Jpn Pharmacol Ther (Suppl) 1991;19:23-30.
16. Hara H, Shimada H, Kitajima A, Tamao Y. Effect of (+/-)-2-(dimethylamino)-1-[[o-(m-methoxyphenethyl)phenoxy] methyl]ethyl hydrogen succinate on experimental models of peripheral obstructive disease. Arzneimittelforschung 1991;41:616-620.
17. Horii D, Hanazuka M, Nakahara H, et al. General pharmacological studies of a new antiplatelet agent, MCI-9042. Jpn Pharmacol Ther 1991;19(Suppl):41-77.
18. Hoyer D, Clarke DE, Fozard JR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). [Review]. Pharmacol Rev 1994;46:157-203.
19. Humphrey PP, Hartig P, Hoyer D. A proposed new nomenclature for 5-HT receptors. [Review]. Trends Pharmacol Sci 1993;14:233-236.
20. Isogai Y, Yokose T, Ikemoto T, et al. Phase-1 study of sarpogrelate hydrochloride (MCI-9042)-Single and repeated oral administration. J Clin Thrap Med 1991;7:1177-1192.
21. Leysen JE. Serotonergic binding sites. In: Vanhoutte PM, ed. Serotonin and Cardiovascular System. New York: Raven Press, 1985.
22. 3H]ketanserin. Eur J Pharmacol 1983;88:125-130.
23. 2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol Pharmacol 1982;21:301-314.
24. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974;290:697-701.
25. Malyszko J, Pawlak K, Malyszko JS, Mysliwiec M, Takada Y, Takada A. MCI-9042 and aggregation of uremic and normal platelets. J Serotonin Res 1996;4:251-258.
26. Malyszko J, Urano T, Knofler R, et al. Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes. Thromb Res 1994;75:569-576.
27. Maruyama K, Kinami J, Sugita Y, et al. MCI-9042: High affinity for serotonergic receptors as assessed by radioligand binding assay. J Pharmacobiol Dyn 1991;14:177-181.
28. Pietraszek MH, Kawamura H, Taminato T, Takada Y, Takada A. Enhanced platelet response to serotonin in diabetes mellitus in relationship to vascular complications. Thromb Hemost 1991;65:985.
29. Pietraszek MH, Takada Y, Takada A, et al. Blood serotonergic mechanisms in type 2 (non-insulin dependent) diabetes mellitus. Thromb Res 1992;66:765-774.
30. Pietraszek MH, Takada Y, Taminato A, Yoshimi T, Watanabe I, Takada A. The effect of MCI-9042 on serotonin-induced platelet aggregation in type 2 diabetes mellitus. Thromb Res 1993;70:131-138.
31. Rappaport RM, Green AA, Page IH. Serum vasoconstrictor (serotonin). IV. Isolation and characterization. J Biol Chem 1948;176:1243-1251.
32. 2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function in Buerger's disease. Thromb Res (in press).
33. Schotte A, Maloteaux JM, Laduron PM. Characterization and regional distribution of serotonin S2-receptors in human brain. Brain Res 1983;276:231-235.
34. Sebekova K, Raucinova M, Dzurik R. Serotonin metabolism in patients with decreased renal function. Nephron 1989;53:229-232.
35. Shimada H, Hara H, Tamao Y. Inhibitory effect of sarpogrelate hydrochloride on serotonin-induced intracellular free calcium elevation of rat platelets. Jpn Pharmacol Ther (in Japanese) 1991;19(Suppl):11-15.
36. Takada A, Takada Y, Urano T, Hishida A, Ohara Ke, Ohara Ko. Relationship between serum lipids and plasma or blood serotonin levels in normal volunteers and nephrotic and depressive patients. In: Takada A, Curzon G, eds. Serotonin in the Central Nervous System and Periphery. Amsterdam: Elsevier Science BV, 1995.
37. Takada Y, Urano T, Watanabe I, Taminato A, Yoshimi T, Takada A. Changes in fibrinolylic parameters in male patients with type 2 (non-insulin-dependent) diabetes mellitus. Thromb Res 1993;71:405-415.
38. 2 serotonin receptors. Eur J Pharmacol 1985;117:145-146.
39. 3H] ketanserin for serotonin-2 receptor in the rabbit platelet. J Pharmacobiol Dyn 1991;14:461-466.
40. Van Nueten JM, Janssen PAJ, Symoens J, et al: Ketanserin. In: Scriabine A, ed. New Cardiovasc Drugs New York: Raven Press, 1987.
41. 1-adrenergic receptor activities at vascular sites. J Cardiovasc Pharmacol 1988;11:10-15.